STRIDE: Semaglutide Reduces Progression of PAD by 54% in Type 2 Diabetes
New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.
Related Articles
Closed-Loop Therapy Improves Glycemic Control in Pregnant Women with T1D
A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.
STEP UP: Higher Semaglutide Doses Yield Greater Weight Loss in Obesity
Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.
ACHIEVE-1: Oral GLP-1 Agonist Orforglipron Shows Strong HbA1c, Weight Reductions
The ACHIEVE-1 trial reveals orforglipron’s potential as a breakthrough treatment for type 2 diabetes.
Amycretin Data at ADA Highlight Efficacy, Safety of Dual-Agonist Obesity Therapy
New research reveals amycretin’s promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.
ADA Symposium Focuses on New Guidelines for SOC of Overweight and Obesity
New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.
Zimislecel Enables Insulin Independence in 10 Participants with Type 1 Diabetes
Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.
Evolving Care for T1D in Pregnancy, with Lois Donovan, MD, and Denise Feig, MD, MSc
Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.
Personalized Diabetes Prevention: Insights from 15 Years of the VA MOVE! Program, with Qiaochu Xue, PhD, MPH
Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.
ACHIEVE-1: Oral GLP-1 Agonist Orforglipron Shows Strong HbA1c, Weight Reductions
The ACHIEVE-1 trial reveals orforglipron’s potential as a breakthrough treatment for type 2 diabetes, showcasing significant improvements in glycemic control and weight loss.
STEP UP: Higher Semaglutide Doses Yield Greater Weight Loss in Obesity
Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.